Novo Holdings appoints two life science sector leaders to its advisory group
Novo Holdings A/S is very pleased to announce the appointment of Richard Ridinger (left), former CEO of Lonza Group, and David Martyr, former CEO of Tecan, as new members of its advisory group, the Novo Advisory Group.
Until April 2019, Richard Ridinger was the CEO of Lonza Group, a Switzerland-based leader in the provision of biotechnology and biochemistry products and solutions to the life sciences industry. Under Richard Ridinger’s seven-year leadership, the market value of Lonza increased by almost eightfold.
David Martyr was, until recently, the CEO of Tecan, a leading global provider of automated laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. David Martyr has a wealth of experience in the laboratory and diagnostics sectors, which are areas of focus for Novo Holdings. Prior to his position at Tecan, David Martyr was Group President of Leica Microsystems, a leading company specializing in microscopes and microscopy imaging equipment for medical, scientific and industrial use.
Kasim Kutay, CEO of Novo Holdings, says: “I am very pleased that Richard Ridinger and David Martyr are joining the Novo Advisory Group. They both have highly impressive track records and have been at the forefront of outstanding value creation in their respective companies in recent years. Richard Ridinger and David Martyr bring in-depth knowledge and expertise in sectors that are of strategic importance to Novo Holdings and will add very important capabilities to the Novo Advisory Group.”
“The addition of Richard Ridinger and David Martyr is part of the ongoing expansion of the Novo Advisory Group as Novo Holdings continues to increase its life science investments,” adds Kasim Kutay.
Richard Ridinger says: “I have known the Novo Holdings team for several years, and I am delighted to be joining a group with such an impressive investment track record and powerful purpose.”
David Martyr says: “I am very pleased to be joining the Novo Advisory Group. In particular, I look forward to using my experience from the laboratory and diagnostics sectors to assist Novo Holdings with their investments in these sectors.”
About Richard Ridinger
2016–: Non-Executive Director, Firmenich
2012–2019: Chief Executive Officer, Lonza Group
2002–2011: Executive Vice President, Cognis
1986–2001: Vice President, Henkel
1985: Master of Engineering, Chemical Engineering,
Karlsruher Institut für Technologie, Germany
About David Martyr
2012–2019: Chief Executive Officer, Tecan
2016–2018: Non-Executive Director, BÜCHI Labortechnik AG
2015–2018: Non-Executive Chairman, Sphere Medical Holding plc
2009–2012: VP & Group Executive, Danaher Corporation
1998–2012: President, Leica Microsystems Group
1989–1998: Managing Director, Europe, Lumonics Limited
1983: PhD, University of Newcastle upon Tyne, UK
1979: First Class BSc, University of Newcastle upon Tyne, UK
Christian Mostrup Scheel, Senior Press Officer, phone: +45 3067 4805, email@example.com.